Phio Pharmaceuticals (PHIO)

Executive Summary

Phio Pharmaceuticals is a clinical-stage biotechnology company pioneering self-delivering siRNA therapeutics based on the Nobel Prize-winning RNAi technology. Its proprietary INTASYL platform enables precise gene silencing without the need for complex delivery vehicles, addressing a key limitation of traditional RNAi therapies. The company is focused on reawakening the immune system against cancer by targeting immune checkpoints and oncogenic drivers in solid tumors, representing a novel approach to immuno-oncology. Phio currently has two active Phase 1 trials: PH-762 for cutaneous squamous cell carcinoma and other skin cancers, and a DP CD8 TIL therapy combined with low-dose IL-2 for HNSCC and other solid tumors. Both trials are ongoing, with PH-762 expected to report initial data in the near term. The company maintains a lean operational model and has a low market valuation of approximately $14 million, reflecting its early stage but also offering significant upside potential if clinical data are positive. Key upcoming catalysts include data readouts and potential partnering or financing activities to extend the cash runway.

Upcoming Catalysts (preview)

• Q2 2026PH-762 Phase 1 Data Readout in Skin Cancers40% success
• H2 2026DP CD8 TIL Therapy Interim Data35% success
• 2026Potential Partnership or Financing30% success